Mesenchymal stromal cells in animal bleomycin pulmonary fibrosis models: A systematic review

Stem Cells Translational Medicine

Volumn 4, Issue 12, 2015, Pages 1500-1510

  Srour, Nadim ^a,b,c,d,e   Thébaud, Bernard ^f,g,h  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b HÔPITAL CHARLES LEMOYNE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

^d and a member of the Respiratory Medicine Program Committee of the College of Family Physicians of Canada   (Canada)

^e The Ottawa Hospital Research Institute ^*  (Canada)

^f OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^g CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^h UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Animal studies; Idiopathic pulmonary fibrosis; Stem cells; Systematic review; Therapy

Indexed keywords

COLLAGENASE 3; GELATINASE A; GELATINASE B; INTERLEUKIN 1; INTERLEUKIN 6; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; BLEOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEOMYCIN-INDUCED PULMONARY FIBROSIS; CLINICAL TRIAL (TOPIC); FIBROBLAST; HUMAN; LUNG LAVAGE; MESENCHYMAL STROMA CELL; NEUTROPHIL COUNT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); STEM CELL TRANSPLANTATION; SURVIVAL; SYSTEMATIC REVIEW; ANIMAL; CHEMICALLY INDUCED; DISEASE MODEL; EMBRYONIC STEM CELL; INDUCED PLURIPOTENT STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; METABOLISM; PATHOLOGY; PULMONARY FIBROSIS; TRANSPLANTATION;

ANIMALS; BLEOMYCIN; DISEASE MODELS, ANIMAL; EMBRYONIC STEM CELLS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PULMONARY FIBROSIS;

EID: 84949673435     PISSN: 21576564     EISSN: 21576580     Source Type: Journal    
DOI: 10.5966/sctm.2015-0121     Document Type: Article

References (57)

1. Raghu G, Chen S-Y, Yeh W-S et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: Incidence, prevalence, andsurvival,2001-11. LancetRespirMed2014;2: 566–572.
2. Tzouvelekis A, Bonella F, Spagnolo P. Update on therapeutic management of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2015; 11:359–370.
3. King TE Jr., Bradford WZ, Castro-Bernardini S et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2083–2092.
4. Richeldi L, duBois RM, Raghu G et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014;370:2071–2082.
5. Kingwell K. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nat Rev Drug Discov 2014;13:483–484.
6. Staitieh BS, Renzoni EA, Veeraraghavan S. Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Ann Med 2015; 47:100–105.
7. Bonfield TL, Nolan Koloze MT, Lennon DP et al. Defining human mesenchymal stem cell efficacy in vivo. J Inflamm (Lond) 2010;7:51.
8. Ionescu LI, Alphonse RS, Arizmendi N et al. Airway delivery of soluble factors from plastic-adherent bone marrow cells prevents murine asthma. Am J Respir Cell Mol Biol 2012;46:207–216.
9. Friedrich JO, Adhikari NK, Beyene J. Ratio of means for analyzing continuous outcomes in meta-analysis performed as well as mean difference methods. J Clin Epidemiol 2011;64: 556–564.
10. Gazdhar A, Susuri N, Hostettler K et al.HGF expressing stem cells in usual interstitial pneumonia originate from the bonemarrow and are antifibrotic. PLoS One 2013;8:e65453.
11. Jun D, Garat C, West J et al. The pathology of bleomycin-induced fibrosis is associated with loss of resident lung mesenchymal stem cells that regulate effector T-cell proliferation. STEM CELLS 2011;29:725–735.
12. Kumamoto M, Nishiwaki T, Matsuo N et al. Minimally cultured bone marrow mesenchymal stemcells ameliorate fibrotic lung injury. Eur Respir J 2009;34:740–748.
13. Ono M, Ohkouchi S, Kanehira M et al. Mesenchymal stem cells correct inappropriate epithelial-mesenchyme relation in pulmonary fibrosis using stanniocalcin-1. Mol Ther 2015; 23:549–560.
14. Gao F, Li Q, Hou L et al.Mesenchymal stem cell-based angiotensin-converting enzyme 2 in treatment of acute lung injury rat induced by bleomycin. Exp Lung Res 2014;40:392–403.
15. Lee SH, Jang AS, Kim YE et al. Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis. Respir Res 2010;11:16.
16. Ortiz LA, Gambelli F, McBride C et al. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA 2003;100:8407–8411.
17. Moodley Y, Vaghjiani V, Chan J et al. Antiinflammatory effects of adult stem cells in sustained lung injury: A comparative study. PLoS One 2013;8:e69299.
18. Lee SH, Lee EJ, Lee SY et al. The effect of adipose stem cell therapy on pulmonary fibrosis induced by repetitive intratracheal bleomycin in mice. Exp Lung Res 2014;40:117–125.
19. Aguilar S, Scotton CJ, McNulty K et al. Bone marrow stem cells expressing keratinocyte growth factor via an inducible lentivirus protects against bleomycin-induced pulmonary fibrosis. PLoS One 2009;4:e8013.
20. Garcia O, Carraro G, Turcatel G et al. Amniotic fluid stem cells inhibit the progression of bleomycin-induced pulmonary fibrosis via CCL2 modulation in bronchoalveolar lavage. PLoS One 2013;8:e71679.
21. Cargnoni A, Gibelli L, Tosini A et al. Transplantation of allogeneic and xenogeneic placenta-derived cells reduces bleomycininduced lung fibrosis. Cell Transplant 2009;18: 405–422.
22. Zhao F, Zhang YF, Liu YG et al. Therapeutic effects of bone marrow-derived mesenchymal stem cells engraftment on bleomycin-induced lung injury in rats. Transplant Proc 2008;40: 1700–1705.
23. Huang K, Kang X, Wang X et al. Conversion of bone marrow mesenchymal stem cells into type II alveolar epithelial cells reduces pulmonary fibrosis by decreasing oxidative stress in rats. Mol Med Rep 2015;11:1685–1692.
24. Moodley Y, Atienza D, Manuelpillai U et al. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Am J Pathol 2009;175:303–313.
25. Min F, Gao F, LiQet al. Therapeutic effect of human umbilical cord mesenchymal stem cells modified by angiotensin-converting enzyme 2 gene on bleomycin-induced lung fibrosis injury. Mol Med Rep 2015;11:2387–2396.
26. Ortiz LA, Dutreil M, Fattman C et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA 2007;104:11002–11007.
27. Germano D, Blyszczuk P, Valaperti A et al. Prominin-1/CD133+ lung epithelial progenitors protect frombleomycin-induced pulmonary fibrosis. AmJ Respir Crit CareMed 2009;179:939–949.
28. Choi M, Ban T, Rhim T. Therapeutic use of stem cell transplantation for cell replacement or cytoprotective effect of microvesicle released from mesenchymal stem cell. Mol Cells 2014;37:133–139.
29. Bailo M, Soncini M, Vertua E et al. Engraftment potential of human amnion and chorion cells derived from term placenta. Transplantation 2004;78:1439–1448.
30. Srour N, Thébaud B. Stem cells in animal asthma models: A systematic review. Cytotherapy 2014;16:1629–1642.
31. Ahmad T, Mukherjee S, Pattnaik B et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. EMBO J 2014;33:994–1010.
32. How CK, Chien Y, Yang KY et al. Induced pluripotent stem cells mediate the release of interferon gamma-induced protein 10 and alleviate bleomycin-induced lung inflammation and fibrosis. Shock 2013;39:261–270.
33. Nakashima T, Liu T, Yu H et al. Lung bone marrow-derived hematopoietic progenitor cells enhance pulmonary fibrosis. Am J Respir Crit Care Med 2013;188:976–984.
34. Tang N, Zhao Y, Feng R et al. Lysophosphatidic acid accelerates lung fibrosis by inducing differentiation of mesenchymal stem cells into myofibroblasts. J Cell Mol Med 2014;18: 156–169.
35. Marriott S, Baskir RS, Gaskill C et al. ABCG2pos lung mesenchymal stem cells are a novel pericyte subpopulation that contributes to fibrotic remodeling. Am J Physiol Cell Physiol 2014;307:C684–C698.
36. Skurikhin EG, Khmelevskaya ES, Pershina OV et al. Differentiation of mesenchymal multipotent stromal cells of the lungs in pneumofibrosis. Bull Exp Biol Med 2013;154:537–543.
37. Blyszczuk P, Germano D, Stein S et al. Profibrotic potential of prominin-1+ epithelial progenitor cells in pulmonary fibrosis. Respir Res 2011;12:126.
38. Lee JS, Hong JM, Moon GJ et al. A longterm follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. STEM CELLS 2010;28:1099–1106.
39. Wakitani S, Okabe T, Horibe S et al. Safety of autologousbone marrow-derived mesenchymal stem cell transplantation for cartilage repair in 41 patients with 45 joints followed for up to 11 years and 5 months. J Tissue Eng Regen Med 2011;5:146–150.
40. Lalu MM, McIntyre L, Pugliese C et al. Safety of cell therapy with mesenchymal stromal cells (SafeCell): A systematic review and metaanalysis of clinical trials. PLoSOne 2012;7:e47559.
41. Glasziou P, Altman DG, Bossuyt P et al. Reducingwastefromincompleteorunusablereports of biomedical research. Lancet2014;383:267–276.
42. Kilkenny C, Browne WJ, Cuthill IC et al. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol 2010;8:e1000412.
43. Weiss DJ, Casaburi R, Flannery R et al. A placebo-controlled, randomized trial of mesenchymal stem cells in COPD. Chest 2013;143: 1590–1598.
44. Gotts JE, Matthay MA. Cell therapy for lung disease: A step forward. Chest 2013;143: 1525–1527.
45. Tzouvelekis A, Paspaliaris V, Koliakos G et al. A prospective, non-randomized, no placebo-controlled, phase Ib clinical trial to study the safety of the adipose derived stromal cellsstromal vascular fraction in idiopathic pulmonary fibrosis. J Transl Med 2013;11:171.
46. Ilić N, Atkinson K. Manufacturing and use of human placenta-derived mesenchymal stromal cells for phase I clinical trials: Establishment and evaluation of a protocol. Vojnosanit Pregl 2014; 71:651–659.
47. Chambers DC, Enever D, Ilic N et al. A phase 1b study of mesenchymal stromal cell therapy for idiopathic pulmonary fibrosis. Cytotherapy 2014;16:S12.
48. Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials. Lancet 2011;377:1760–1769.
49. Song JW, Hong SB, Lim CM et al. Acute exacerbation of idiopathic pulmonary fibrosis: Incidence, risk factors and outcome. Eur Respir J 2011;37:356–363.
50. Moore BB, Fry C, Zhou Y et al. Inflammatory leukocyte phenotypes correlate with disease progression in idiopathic pulmonary fibrosis. Front Med 2014;1:1.
51. Wang Y, Chen X, Cao W et al. Plasticity of mesenchymal stem cells in immunomodulation: Pathological and therapeutic implications. Nat Immunol 2014;15:1009–1016.
52. Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on procollagen gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther 1999;289:211–218.
53. Schelegle ES, Mansoor JK, Giri S. Pirfenidone attenuates bleomycin-induced changes in pulmonary functions in hamsters. Proc Soc Exp Biol Med 1997;216:392–397.
54. Gurujeyalakshmi G, Hollinger MA, Giri SN. Pirfenidone inhibits PDGF isoforms in bleomycin hamster model of lung fibrosis at the translational level. Am J Physiol 1999;276: L311–L318.
55. Oku H, Shimizu T, Kawabata T et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol 2008;590: 400–408.
56. Kakugawa T, Mukae H, Hayashi T et al. Pirfenidone attenuates expression of HSP47 in murine bleomycin-induced pulmonary fibrosis. Eur Respir J 2004;24:57–65.
57. Iyer SN, Margolin SB, Hyde DM et al. Lung fibrosis is ameliorated by pirfenidone fed in diet after the second dose in a threedose bleomycin-hamster model. Exp Lung Res 1998;24:119–132.